Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12276689 | 0.77 | GPR35 (0.52) | PIK3C3LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL23912815 | 0.76 | PIK3C3 (0.34) | PIK3C3NPC1ALDH1A1 | |
| SCHEMBL16913865 | 0.75 | PIK3C3 (0.58) | PIK3C3 | |
| SCHEMBL30481961 | 0.73 | PTK2 (0.40) | PIK3C3ALDH1A1TDP1 | |
| SCHEMBL25323093 | 0.73 | PTK2 (0.40) | PIK3C3ALDH1A1TDP1 | |
| SCHEMBL16913988 | 0.73 | PIK3C3 (1.00) | PIK3C3 | |
| Water SCHEMBL25321793 | 0.70 | PTK2 (0.37) | PIK3C3ALDH1A1TDP1 | |
| SCHEMBL15205496 | 0.69 | SNCA (0.46) | LMNANPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4484518 | 0.69 | RXFP1 (0.57) | NPC1RAB9AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL28148955 | 0.67 | LCK (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105916503-B | Heteroaryl compounds and uses thereof | 米伦纽姆医药公司 | 2020-04-14 | — | — | CN | disclosed |
| US-10538533-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-3094325-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| WO-2015108861-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015108861-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3C3 1186/4885LMNA 3743/4885NPC1 33/4885 |
| US-10538533-B2 | Heteroaryls and uses thereof | VPS35, VPS4B, VPS26B | PIK3C3 1186/4885LMNA 3743/4885NPC1 33/4885 |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3C3 1186/4885LMNA 3743/4885NPC1 33/4885 |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3C3 1186/4885LMNA 3743/4885NPC1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.